SWiss Evaluation of Bioabsorbable Polymer-coated Everolimus-eluting Coronary sTent The SWEET Registry
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Coronary Artery Disease
- Sponsor
- University of Freiburg
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- MACE
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
Bioresorbable polymer drug eluting stents (DES) are an indisputable improvement over first-generation DES with promising results on long-term adverse events. But the thicker polymer and/or strut may hinder its deliverability. Complex procedures challenge stent deliverability and stent delivery failure impacts clinical prognosis.
This registry aimed to assess the immediate performance of the third-generation Synergy everolimus-eluting stent (sEES) and its 12-month clinical follow-up in an all-comer population.
Detailed Description
All consecutive patients treated with the SYNERGY stent at our institutions were prospectively included in the SWEET registry. Baseline and procedural characteristics were collected at index procedure. Clinical follow-up was performed at 1 month and 1 year by clinic visit or follow-up call. The study end point was a composite of cardiac death (CD), myocardial infarction (MI) and target lesion revascularization (TLR) at 1 year.
Investigators
Stéphane Cook, Prof
Professor
University of Freiburg
Eligibility Criteria
Inclusion Criteria
- •1.Patient treated by everolimus-eluting SYNERGY® stent
Exclusion Criteria
- •Patient or legal guardian won't give consent to use collected data
Outcomes
Primary Outcomes
MACE
Time Frame: at 12 month follow up
12-month device-oriented MACE (dMACE) as defined by ARC (cardiac death, MI and TLR).